RegeneRx Biopharmaceuticals, Inc. · OTC:RGRX

RegeneRx Biopharmaceuticals — Shareholder Meeting (July 2008)

19 slides from RegeneRx Biopharmaceuticals's shareholder meeting presentation, Jul 2, 2008

  1. Slide 1: 2008 Annual Shareholders' Meeting

    Slide 1: 2008 Annual Shareholders' Meeting

    2008 Annual Shareholders’ Meeting July 2, 2008

  2. Slide 2: Forward Looking Statement

    Slide 2: Forward Looking Statement

    2 Forward Looking Statement This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Exampl

  3. Slide 3: Our Mission

    Slide 3: Our Mission

    3 To develop and commercialize novel pharmaceutical products that prevent or repair tissue and organ damage caused by disease, trauma, or other pathology. Our Mission

  4. Slide 4: Company Background

    Slide 4: Company Background

    4 Company Background Unique peptide company addressing large markets and orphan indications having unmet medical needs - RGN-137 - Topical gel - RGN-259 - Sterile eye drop - RGN-352 - Parenteral (injectable) Robust clinical program - Three Phase II dermal trials underway - Phase II ophthalmic trial

  5. Slide 5: Management

    Slide 5: Management

    5 Management Dr. Allan Goldstein – Chairman & Chief Scientific Advisor - Founder of RegeneRx, Discoverer of T a 1 and Tß4 - Chairman of Biochemistry and Molecular Biology, George Washington Univ School of Medicine - Author of over 400 scientific articles; inventor of more than 25 U.S. Patents J.J. F

  6. Slide 6: Scientific Advisory Board

    Slide 6: Scientific Advisory Board

    6 Scientific Advisory Board Allan Goldstein, PhD – Chairman & Chief Scientific Advisor - Professor and Chair, Dept of Biochemistry and Molecular Bio, GWU Med School, Washington, DC Herve Byron, MD, MSc - Ophthalmologist in private practice, editorial board of several medical journals specializing in

  7. Slide 7: 2007-2008 Highlights

    Slide 7: 2007-2008 Highlights

    7 2007-2008 Highlights Received two INDs to begin a Phase II ophthalmic wound healing clinical trial and a Phase IA parenteral (injectable) clinical trial, both of which are enrolling patients Implemented numeric naming for our current drug products to differentiate between formulations and create a

  8. Slide 8: 2007-2008 Highlights

    Slide 8: 2007-2008 Highlights

    8 2007-2008 Highlights Numerous papers published on basic research and therapeutic potential of Tß4: – most notable was the cardiovascular research presented at an American Heart Association meeting in November highlighting Tß4’s cardio-protective capabilities in an ischemia-reperfusion pig model, f

  9. Slide 9: 2007-2008 Highlights

    Slide 9: 2007-2008 Highlights

    9 2007-2008 Highlights RegeneRx executives gave corporate presentations at numerous industry and investment banking venues in 2007, including: – BIO 2007 Investor Forum – BIO 2007 Business Forum – 20th Annual Symposium on Advanced Wound Care – First Annual Symposium on Thymosins in Health and Diseas

  10. Slide 10: Research and Development Collaborations

    Slide 10: Research and Development Collaborations

    10 Research and Development Collaborations 18 Active Research Collaborations, Others in Discussion Ophthalmic repair U.S. Military (JG) Stem cell – cardiovascular European University Cosmeceuticals Mexico Dermal Company Ophthalmic mechanisms of repair Midwest University Medical School (GS) Renal fib

  11. Slide 11: RegeneRx Technology Platform

    Slide 11: RegeneRx Technology Platform

    11 RegeneRx Technology Platform Thymosin Beta 4 (Tß4) Naturally occurring, conserved molecule (identical across all species), found in every cell except red blood cells - highest concentration in blood platelets Key Actin regulator in mammals: – Actin plays central role in cell structure and movemen

  12. Slide 12: Product Formulations and Targets

    Slide 12: Product Formulations and Targets

    12 Product Formulations and Targets Multiple Formulations = Multiple Opportunities • Vitrectomy • Sjögren’s Dry Eye • Corneal Surgery • Recurrent Corneal Erosions • Acute M.I. • Ischemic Stroke • Crohn’s • EB • Ulcerative Colitis • Ischemic Renal Disease • Venous Statis Ulcers • EB • Diabetic Ulcers

  13. Slide 13: Clinical Pipeline

    Slide 13: Clinical Pipeline

    13 Clinical Pipeline RGN Is Sponsoring 5 Clinical Trials for Multiple Indications Indications Preclinical Phase I Phase II Enrollment targeted Pressure Ulcers (72 patients) Venous Stasis Ulcers (72 patients) Epidermolysis Bullosa (36 patients) Corneal Wound Healing associated with diabetic vitrectom

  14. Slide 14: Clinical Overview – RGN-137 (Dermal)

    Slide 14: Clinical Overview – RGN-137 (Dermal)

    14 Clinical Overview – RGN-137 (Dermal) Phase I dermal safety – no dose-limiting AEs – 15 healthy volunteers Phase II Recurrent Pressure Ulcers – 72–patient trial ongoing – currently enrolling patients, up to 20 U.S. sites – Randomized, double-blind, placebo-controlled, dose-escalation, 84–day treat

  15. Slide 15: Clinical Overview – RGN-259 (Ophthalmic) and RGN-352 (Parenteral)

    Slide 15: Clinical Overview – RGN-259 (Ophthalmic) and RGN-352 (Parenteral)

    15 Clinical Overview – RGN–259 (Ophthalmic) and RGN–352 (Parenteral) Phase II Corneal Wound Healing Post Vitrectomy – 48–patient trial – enrolling patients, 14 U.S. sites – Randomized, double–blind, placebo–controlled, dose–escalation, 14 day treatment period – Target enrollment completion: Q4 2008

  16. Slide 16: IP Overview

    Slide 16: IP Overview

    16 IP Overview RegeneRx has strong patent portfolio addressing Tissue Protection & Repair opportunities Obtained world-wide intellectual property rights under an exclusive license from NIH in 1999 Filed over 60 patent applications worldwide related to Tß4, active fragments, compositions of matter, c

  17. Slide 17: RegeneRx Business & Partnering Strategy

    Slide 17: RegeneRx Business & Partnering Strategy

    17 RegeneRx Business & Partnering Strategy Outsourcing business model – adds value, cost-effective - CROs conducting Phase II dermal trials, Phase II ophthalmic trial and Phase I parenteral trial - Use outside contractors for manufacturing, formulation, tox and pk studies, etc. • Tß4, analogues and

  18. Slide 18: Summary

    Slide 18: Summary

    18 Summary Unique peptide drug candidate addresses multiple large and certain niche markets, all with unmet needs - Dermal, ophthalmic, parenteral indications (potential future myocardial infarction trial) 53+ scientific publications and presentations in peer-reviewed journals and at scientific meet

  19. Slide 19: RegeneRx

    Slide 19: RegeneRx

    REGENERX

Source: SEC EDGAR · 8-K filed Jul 2, 2008

More decks from RegeneRx Biopharmaceuticals, Inc.

All 8 RegeneRx Biopharmaceuticals decks